Quest Diagnostics Resultados de beneficios anteriores
Pasado controles de criterios 3/6
Los beneficios de Quest Diagnostics han disminuido a una tasa media anual de -20.3%, mientras que en la industria Healthcare los beneficios crecieron en un 9.9% anualmente. Los ingresos han ido disminuyendo a una tasa media de 0.3% al año. La rentabilidad financiera de Quest Diagnostics es de 13.9%, y sus márgenes netos son de 9%.
Información clave
-20.28%
Tasa de crecimiento de los beneficios
-16.08%
Tasa de crecimiento del BPA
| Crecimiento de la industria Healthcare | 8.50% |
| Tasa de crecimiento de los ingresos | -0.32% |
| Rentabilidad financiera | 13.88% |
| Margen neto | 9.04% |
| Última actualización de beneficios | 31 Mar 2026 |
Actualizaciones de resultados anteriores recientes
Recent updates
Quest Diagnostics: Good Q1, Solid Business, Steady Share Price Upside Likely
Apr 24
DGX: Organic Guidance And Capital Returns Will Sustain Safe Haven Appeal
Analyst price targets for Quest Diagnostics have been adjusted slightly lower to $218.19 from $218.50, as analysts factor in updated views on revenue growth, profit margins, and long term P/E assumptions following a series of recent target changes across the coverage universe. Analyst Commentary Recent research updates point to a mixed but generally constructive stance on Quest Diagnostics, with multiple target changes and one fresh list inclusion helping to frame how analysts are thinking about valuation, execution, and growth risk.DGX: Organic Guidance And Capital Returns Will Support Safe Haven Profile
Analysts have raised their price targets on Quest Diagnostics by between $5 and $30, largely pointing to recently issued organic revenue growth guidance and viewing the broader diagnostic lab space as a relative safe haven within healthcare services. Analyst Commentary Recent Street research around Quest Diagnostics and its closest peer highlights a constructive setup for the broader diagnostic lab group, with price target moves on Quest generally framed against views that the sector can act as a relative safe haven within healthcare services.DGX: Premium Multiple And Capital Returns Look Supported By Organic Revenue Guidance
Analysts have raised their price targets on Quest Diagnostics by a range of $5 to $30, citing the company’s recent organic revenue growth guidance and viewing the diagnostic testing space as a relative safe haven within healthcare services. Analyst Commentary Recent research on Quest Diagnostics highlights a cluster of higher price targets and an upgrade, with many investors treating large diagnostic labs as a relatively defensive corner of healthcare services.DGX: Fair Outlook As Premium Multiple And Capital Returns Shape Future Earnings
Analysts raised their price target on Quest Diagnostics by about $1 to $218.50, reflecting refined assumptions that include slightly higher revenue growth, a similar discount rate, modestly adjusted profit margins, and a small change in future P/E expectations, supported by broadly positive recent research across the diagnostic lab space. Analyst Commentary Street research around Quest Diagnostics has focused on how the company is positioned within the broader diagnostic lab group, with recent moves in peer guidance and a series of price target changes shaping sentiment on both upside potential and execution risk.DGX: Fair Outlook As Higher Payouts And Consumer Labs Support Future Earnings
Analysts have lifted their price target on Quest Diagnostics by about $18, reflecting slightly higher modeled revenue growth and a somewhat richer future P/E assumption, even as projected profit margins are trimmed in line with recent Street research that has broadly raised targets across the lab testing group. Analyst Commentary Bullish analysts have broadly raised their price targets on Quest Diagnostics, reflecting a more constructive view on the lab testing group as a whole and on Quest's positioning within it.DGX: Fair Outlook As Consumer Lab Partnerships And Margins Support Future Earnings
Analysts have inched up their fair value estimate for Quest Diagnostics to about $199 per share, a move they tie to slightly higher margin and P/E assumptions following recent research that points to potential upside to current earnings estimates. Analyst Commentary Recent Street research points to potential upside to current earnings estimates for Quest Diagnostics, which is feeding into a more constructive view on the stock’s valuation and execution risk.DGX: Future Consumer Lab Partnerships And Neurology Tests Will Support Balanced Outlook
Analysts have inched up their price target on Quest Diagnostics to about $198.38 from roughly $198.06, reflecting refreshed assumptions around slightly higher revenue growth, a small adjustment to profit margins, and a near steady forward P/E outlook. What's in the News Hims & Hers Health is offering lab testing that it views as a potential US$1b business, with customers accessing testing through Quest Diagnostics and then receiving results and care plans through the Hims platform (Wall Street Journal).DGX: Future Lab Partnerships And Testing Pipeline Will Support Bullish Outlook
Analysts lifted their price target for Quest Diagnostics by about US$1 to roughly US$198, citing recent Q3 results with sales and earnings ahead of consensus; raised full year guidance; firm organic volume trends; and growing interest in longer term opportunities, such as the Haystack MRD test and a generally supportive lab testing backdrop. Analyst Commentary Street research following the Q3 report points to a generally constructive tone, with multiple firms lifting their price targets and highlighting both execution on current fundamentals and potential longer term growth drivers.DGX: Future Lab Partnerships And Testing Pipeline Will Support Balanced Outlook
Analysts have nudged their price targets on Quest Diagnostics higher by between $5 and $25 per share, citing solid Q3 outperformance, raised guidance, and confidence in organic growth and future testing catalysts. Analyst Commentary Street research following the Q3 print highlights a generally constructive stance on Quest Diagnostics, with most price target increases framed around stronger than expected fundamentals and improving visibility into growth drivers over the next two years.DGX: Future Volume Gains And Lab Partnerships Will Support Balanced Outlook
The analyst price target for Quest Diagnostics was modestly increased to $197.31 from $197.25. Analysts cited stronger-than-expected earnings, raised guidance, and continued positive core trends as the rationale for the update.DGX: Future Revenue Expansion And Partnerships Will Balance Near-Term Risks
Quest Diagnostics saw its analyst price target increase, with several firms now projecting new targets between $195 and $215 per share. Analysts cite strong quarterly results and ongoing positive momentum in core business trends.DGX: Core Volume Momentum And New Blood Tests Will Drive Share Momentum
Quest Diagnostics' analyst fair value estimate has been raised from $191.56 to $197.25 per share. This change reflects analysts' upbeat outlook after strong quarterly results, improved profit margins, and continued momentum in core business trends.Preventive Diagnostics And Automation Will Shape Future Healthcare
Analysts have raised their fair value estimate for Quest Diagnostics from $188.19 to $191.56 per share, citing ongoing stable end markets and improving revenue growth expectations. Analyst Commentary Recent street research has highlighted a mix of optimism and caution surrounding Quest Diagnostics.Earnings Not Telling The Story For Quest Diagnostics Incorporated (NYSE:DGX)
Aug 20
Return Trends At Quest Diagnostics (NYSE:DGX) Aren't Appealing
Jun 21Is Quest Diagnostics Incorporated (NYSE:DGX) Trading At A 48% Discount?
May 11Quest Diagnostics: Good Growth Prospects, But Little To No Upside Left At Current Valuation
Jan 28Quest Diagnostics: Organic Growth Leads To Q3 Earnings Beat
Oct 24Desglose de ingresos y gastos
Cómo gana y gasta dinero Quest Diagnostics. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 31 Mar 26 | 11,278 | 1,020 | 1,955 | 0 |
| 31 Dec 25 | 11,035 | 988 | 1,920 | 0 |
| 30 Sep 25 | 10,850 | 963 | 1,891 | 0 |
| 30 Jun 25 | 10,522 | 945 | 1,832 | 0 |
| 31 Mar 25 | 10,158 | 892 | 1,758 | 0 |
| 31 Dec 24 | 9,872 | 866 | 1,731 | 0 |
| 30 Sep 24 | 9,539 | 838 | 1,681 | 0 |
| 30 Jun 24 | 9,346 | 836 | 1,624 | 0 |
| 31 Mar 24 | 9,287 | 842 | 1,621 | 0 |
| 31 Dec 23 | 9,252 | 850 | 1,630 | 0 |
| 30 Sep 23 | 9,297 | 759 | 1,748 | 0 |
| 30 Jun 23 | 9,488 | 790 | 1,825 | 0 |
| 31 Mar 23 | 9,603 | 789 | 1,832 | 0 |
| 31 Dec 22 | 9,883 | 942 | 1,838 | 0 |
| 30 Sep 22 | 10,294 | 1,230 | 1,736 | 0 |
| 30 Jun 22 | 10,582 | 1,479 | 1,705 | 0 |
| 31 Mar 22 | 10,679 | 1,874 | 1,715 | 0 |
| 31 Dec 21 | 10,788 | 1,988 | 1,723 | 0 |
| 30 Sep 21 | 11,046 | 2,175 | 1,674 | 0 |
| 30 Jun 21 | 11,058 | 2,238 | 1,642 | 0 |
| 31 Mar 21 | 10,335 | 1,794 | 1,571 | 0 |
| 31 Dec 20 | 9,437 | 1,425 | 1,545 | 0 |
| 30 Sep 20 | 8,361 | 1,101 | 1,414 | 0 |
| 30 Jun 20 | 7,531 | 749 | 1,378 | 0 |
| 31 Mar 20 | 7,657 | 771 | 1,376 | 0 |
| 31 Dec 19 | 7,726 | 835 | 1,457 | 0 |
| 30 Sep 19 | 7,639 | 709 | 1,402 | 0 |
| 30 Jun 19 | 7,572 | 707 | 1,406 | 0 |
| 31 Mar 19 | 7,538 | 720 | 1,387 | 0 |
| 31 Dec 18 | 7,531 | 733 | 1,395 | 0 |
| 30 Sep 18 | 7,557 | 860 | 1,378 | 0 |
| 30 Jun 18 | 7,524 | 808 | 1,359 | 0 |
| 31 Mar 18 | 7,469 | 782 | 1,372 | 0 |
| 31 Dec 17 | 7,402 | 769 | 1,421 | 0 |
| 30 Sep 17 | 7,398 | 671 | 1,413 | 0 |
| 30 Jun 17 | 7,427 | 701 | 1,480 | 0 |
| 31 Mar 17 | 7,469 | 702 | 1,558 | 0 |
| 31 Dec 16 | 7,214 | 642 | 1,337 | 0 |
| 30 Sep 16 | 7,503 | 675 | 1,624 | 0 |
| 30 Jun 16 | 7,498 | 825 | 1,637 | 0 |
| 31 Mar 16 | 7,517 | 748 | 1,637 | 0 |
| 31 Dec 15 | 7,493 | 706 | 1,616 | 0 |
| 30 Sep 15 | 7,527 | 703 | 1,654 | 0 |
| 30 Jun 15 | 7,551 | 491 | 1,657 | 0 |
Ingresos de calidad: DGX tiene ganancias de alta calidad.
Margen de beneficios creciente: Los actuales márgenes de beneficio (9%) de DGX son superiores a los del año pasado (8.8%).
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: Los beneficios de DGX han disminuido en un 20.3% al año en los últimos 5 años.
Acelerando crecimiento: El crecimiento de los beneficios de DGX en el último año (14.3%) supera su media de 5 años (-20.3% al año).
Beneficios vs. Industria: El crecimiento de los beneficios de DGX en el último año (14.3%) no superó al de la industria Healthcare 17.2%.
Rentabilidad financiera
Alta ROE: La rentabilidad financiera de DGX (13.9%) se considera baja.
Rentabilidad económica
Rendimiento del capital invertido
Descubre empresas con buenos resultados en el pasado
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/04 16:24 |
| Precio de las acciones al final del día | 2026/05/04 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Quest Diagnostics Incorporated está cubierta por 36 analistas. 16 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Eric Coldwell | Baird |
| Luke Sergott | Barclays |